论文部分内容阅读
目的:评价Perigee系统治疗女性前盆腔器官脱垂的安全性及临床疗效。方法 :对24例盆腔器官脱垂定量系统(pelvic organ prolapse-quantitation,POP-Q)诊断为Ⅱ度或以上的前盆腔器官脱垂患者行Perigee前盆底重建术,采用主观评价[盆底功能障碍影响问卷简版(PFIQ-7)、性生活质量问卷]和客观评价(POP-Q)对围手术期及术后近期各项指标的变化及并发症发生情况进行分析。结果:24例患者的平均手术时间(70.83±15.30)min,术中平均出血(80.92±40.39)ml,术后中位随访时间为4个月。以POP-Q评分作为客观疗效评价指标,治愈率为100%;PFIQ-7评分较术前有显著改善;术后1例有性生活,性生活质量无明显下降。术后发生网片暴露1例(4.2%);新发压力性尿失禁2例(8.4%);会阴部、臀部疼痛4例(16.7%);新发阴道后壁脱垂3例(12.6%);无严重并发症发生。结论:Perigee系统是治疗前盆腔脏器脱垂的安全、微创术式,近期疗效肯定,中远期疗效待进一步随访。
OBJECTIVE: To evaluate the safety and clinical efficacy of Perigee system in treating pelvic organ prolapse in women. Methods: Perigee anterior pelvic floor reconstruction was performed in 24 pelvic organ prolapse-quantitation (POP-Q) patients with anterior pelvic organ prolapse of grade II or higher. Subjective evaluation of pelvic floor function (PFIQ-7), quality of life questionnaire (QOL) and objective evaluation (POP-Q) were used to analyze the changes of perioperative and postoperative short-term indicators and the incidence of complications. Results: The mean operative time (70.83 ± 15.30) min, average bleeding rate (80.92 ± 40.39) ml in 24 patients and postoperative median follow-up time were 4 months. The POP-Q score as an objective evaluation of efficacy indicators, the cure rate was 100%; PFIQ-7 score significantly improved compared with preoperative; 1 case of sexual life, no significant decline in sexual quality. There were 1 case (4.2%) of mesh exposure after surgery, 2 cases of stress urinary incontinence (8.4%), 4 cases of perineal and hip pain (16.7%), 3 cases of new posterior vaginal wall prolapse (12.6% ); No serious complications occurred. Conclusion: The Perigee system is a safe and minimally invasive surgical treatment for pelvic organ prolapse before treatment. The short-term curative effect is sure, and the long-term and long-term therapeutic effects are to be followed up.